Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

A via the Special Protocol Assessment process, each in second-line treatment of advanced prostate cancer, featuring either survival or pain palliation as the primary endpoint. We believe these SPA agreements with the FDA together with our Phase 2 survival data position OGX-011 as an attractive asset. These regulatory achievements along with recent clinical data have supported our discussions with potential development and commercialization partners."

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the first quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 800-967-7143 (U.S. & Canada) or 719-325-2413 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... uses Medical College of Wisconsin technologies and clinical and ... of diagnostics for sepsis and pneumonia. , ,The company, ... will come over the next five years, would enable ... methods, and demonstrate the performance of this new molecular ...
... Brady Corp., a Milwaukee-based identification, safety, graphic systems ... security software developer. , ,Brady did not disclose ... , of San Jose. , ,STOPware, founded in ... and track visitors in a variety of settings, including ...
... Madison, Wis. -- Dr. Carlos Perez has been ... Inc . in Madison. Perez is a former president ... more than 40 years of experience in radiation oncology. ... of Radiation Oncology at Mallinckrodt Institute of Radiology, Siteman ...
Cached Biology Technology:
(Date:8/22/2014)... consumers will finally be able to purchase fuel cell ... zero-emissions vehicles, most of the cars will run on ... contributes to global warming. , Now scientists at Stanford ... an ordinary AAA battery to produce hydrogen by water ... two electrodes that split liquid water into hydrogen and ...
(Date:8/22/2014)... heard of the birds and the bees. But ... are being fertilized. The fertilization process for flowering ... between the male and female reproductive cells. New ... Heidelberg, and Munich, and including Carnegie,s Wolf Frommer, ... the chemical signaling process that guides flowering plant ...
(Date:8/21/2014)... including researchers from the University of Georgia recently published the ... journal Science . Their discovery paves the way for ... farming and industry. , Canola is grown across much ... is increasingly cultivated in Georgia. Canola oil used for cooking ... and rich supply of omega-3 fatty acids, but the plant ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Calcium and reproduction go together 2Canola genome sequence reveals evolutionary 'love triangle' 2
... The Field Museum announced today that it has received 409,416 ... of Monaco Foundation for a three-year project: Establishing new conservation ... biological inventories by The Field Museum,s Environment, Culture, and Conservation ... landscapes in Ecuador, Peru, and Bolivia. Eight of these areas ...
... CryoLife, Inc. (NYSE: CRY) Elite cardiovascular surgeons from around ... the two-day Ross Summit to review and discuss current peer-reviewed ... and to practice the technical nuances required to perform this ... type of specialized aortic valve surgery in which the patient,s ...
... Rush University Medical Center is participating in a ... to determine whether a vitamin-like substance, in high doses, ... disorder that affects about one million people in the ... we have for Parkinson,s can only mask the symptoms ...
Cached Biology News:Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 2Growing outcomes evidence spurs renewed interest in unique heart valve procedure 2Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Biology Products: